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Abstract
Background: Lipids have critical functions in cellular energy storage, structure and signaling. Many individual lipid
molecules have been associated with the evolution of prostate cancer; however, none of them has been approved to be
used as a biomarker. The aim of this study is to identify lipid molecules from hundreds plasma apparent lipid species as
biomarkers for diagnosis of prostate cancer.
Methodology/Principal Findings: Using lipidomics, lipid profiling of 390 individual apparent lipid species was performed
on 141 plasma samples from 105 patients with prostate cancer and 36 male controls. High throughput data generated from
lipidomics were analyzed using bioinformatic and statistical methods. From 390 apparent lipid species, 35 species were
demonstrated to have potential in differentiation of prostate cancer. Within the 35 species, 12 were identified as individual
plasma lipid biomarkers for diagnosis of prostate cancer with a sensitivity above 80%, specificity above 50% and accuracy
above 80%. Using top 15 of 35 potential biomarkers together increased predictive power dramatically in diagnosis of
prostate cancer with a sensitivity of 93.6%, specificity of 90.1% and accuracy of 97.3%. Principal component analysis (PCA)
and hierarchical clustering analysis (HCA) demonstrated that patient and control populations were visually separated by
identified lipid biomarkers. RandomForest and 10-fold cross validation analyses demonstrated that the identified lipid
biomarkers were able to predict unknown populations accurately, and this was not influenced by patient’s age and race.
Three out of 13 lipid classes, phosphatidylethanolamine (PE), ether-linked phosphatidylethanolamine (ePE) and ether-linked
phosphatidylcholine (ePC) could be considered as biomarkers in diagnosis of prostate cancer.
Conclusions/Significance: Using lipidomics and bioinformatic and statistical methods, we have identified a few out of
hundreds plasma apparent lipid molecular species as biomarkers for diagnosis of prostate cancer with a high sensitivity,
specificity and accuracy.
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Introduction
Biomarkers play pivotal roles in the care of patients with
cancers. However, currently used biomarkers for prostate cancer
are sub-optimal. For example, prostate specific antigen (PSA), the
most widely used biomarker, is controversial with regard to its
specificity and sensitivity in various populations [1]. There are also
concerns regarding possible over-diagnosis of prostate cancer by
PSA in patients with limited potential for disease progression [2–
4]. Several new biomarkers are being studied [5–7]; however,
none of these has proven to be useful for clinical testing.
Lipids comprise diverse classes of molecules with critical
functions in cellular energy storage, structure, and signaling.
Previous studies have demonstrated that the risk of prostate cancer
is increased with elevations in particular plasma fatty acids, such as
myristic acid, a-linolenic acid, and eicosapentaenoic acids [8–9].
Many individual polar lipid [10–17] and cholesterol [18–21]
species have been associated with the evolution of prostate cancer.
However, due to limitations in technology, only a few apparent
lipid species or lipid classes were analyzed in each of these studies,
and no attempt has been made to discover lipid molecules as
biomarkers for prostate cancer by large scale lipid profiling. Large
scale lipid profiling was not done until the introduction of mass-
spectrometry-based lipidomics strategies a decade ago [22].
Recently, reference values for 500 plasma lipid species were
obtained from a lipidomics analysis of the pooled and blended
plasma from 100 healthy people [23]. Lipidomics has been
demonstrated to be a useful tool in the study of mechanisms and
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biomarkers in many diseases such as obesity [24–25], atheroscle-
rosis [26–28], hypertension [29], diabetes [30], cystic fibrosis [31]
and other cancers [32–34]. As well, using shotgun lipidomics, a
few lipid species from 70 phospholipids species in urine were
identified as potential markers for prostate cancer [35]. However,
large scale plasma lipid profiling has not been performed on blood
and prostatic samples from patients with prostate cancer.
As described herein, we performed a global lipid profiling,
which included measurement of 340 phospholipid and 50
cholesteryl ester (CE) apparent lipid molecular species, on 141
plasma samples from 105 patients with prostate cancer and 36
male controls. By analysis with bioinformatic and statistical
methods, a few plasma lipid species have been selected as
biomarkers. The initial study demonstrates that these biomarkers




We hypothesize that prostate cancer tissues have distinct lipid
profiles to meet special needs for tumor survival and progression.
Distinctive lipid profiles will influence systemic lipid homeostasis
and be reflected in body fluids including plasma. Therefore,
detection of plasma apparent lipid molecular species will reflect the
existence and progression of prostate cancer. By comparing
plasma concentrations of hundreds of apparent lipid species
among populations with and without prostate cancer, a few
apparent lipid species that are the most representative of cancer
status will be identified as plasma lipid biomarkers in diagnosis of
prostate cancer.
Patients and Sample Collection
One hundred and five (105) plasma samples from 105 patients
with prostate cancer were obtained from the Cooperative Human
Tissue Network (CHTN), where plasma samples were pre-
collected from different clinics during the period from 2004–
2007. Before collection of plasma samples, patients had given
consent and had not undergone therapeutic interventions.
Diagnosis of prostate cancer for each patient was confirmed by
subsequent prostate biopsy or prostatectomy. Limited information
for each patient, including the patient’s age, race and pathological
diagnosis, was provided. Thirty six (36) plasma samples from male
controls were obtained from a collaborating author, who pre-
collected the plasma from 36 male patients at a community clinic,
where patients had their wellness checks or sought for medical help
for other diseases during the period 2006–2008. Criteria for
selection of controls were no history of prostate cancer, denial of
clinical manifestations of prostate cancer, and a low level of serum
PSA. The same protocol for collection of plasma was used in
collection of plasma samples from patients and controls: from each
subject, 10 ml whole blood was collected into a vacutainer tube
containing potassium-EDTA as anticoagulant. The plasma was
promptly separated (no more than 4 h after collection of whole
blood) and stored at 280uC immediately. All plasma samples were
transported on dry ice to the Kansas Lipidomics Research Center
(KLRC) for lipid analysis.
ESI-MS/MS Lipid Profiling
An automated electrospray ionization-tandem mass spectrom-
etry approach was used. In this approach, plasma lipid species are
identified at level of head group plus total acyl carbons: total
double bonds. The detected intensities, each defined by an intact
ion mass/charge (m/z) and a characteristic fragment m/z, are
herein described as ‘‘apparent lipid molecular species’’. Data
acquisition and analysis were carried out as described previously
[36–37] with modifications. Briefly, an aliquot of 3 ml of plasma
was used. Precise amounts of internal standards, obtained and
quantified as previously described [38], were added in the
following quantities (with some small variation in amounts in
different batches of internal standards): 0.60 nmol PC(12:0/12:0),
0.60 nmol PC(24:1/24:1), 0.60 nmol LPC(13:0), 0.60 nmol
LPC(19:0), 0.30 nmol PE(12:0/12:0), 0.30 nmol PE(23:0/23:0),
0.30 nmol LPE(14:0), 0.30 nmol LPE(18:0), 0.30 nmol LPG(14:0),
0.30 nmol LPG(18:0), 0.30 nmol PA(14:0/14:0), 0.30 nmol PA
(phytanoyl/phytanoyl), i.e. PA(20:0/20:0), 0.20 nmol PS(14:0/
14:0), 0.20 nmol PS(phytanoyl/phytanoyl), i.e. PS(20:0/20:0),
0.23 nmol PI (16:0/18:0), 2.5 nmol CE(13:0) and 2.5 nmol
CE(23:0). The sample and internal standard mixture were
combined with solvents, such that the ratio of chloroform/
methanol/300 mM ammonium acetate in water was 300/665/35,
and the final volume was 1.2 ml. This mixture, in autosampler
vials, was centrifuged for 15 min to pellet particulates before
presenting the lipid/solvent mixture to the autosampler. These
unfractionated lipid extracts were introduced by continuous
infusion into the ESI source on a triple quadrupole MS/MS
(API 4000, Applied Biosystems, Foster City, CA), using an
autosampler (LC Mini PAL, CTC Analytics AG, Zwingen,
Switzerland) fitted with the required injection loop for the
acquisition time and presented to the ESI needle at 30 ml/min.
Sequential precursor and neutral loss scans of the extracts
produced a series of spectra with each spectrum revealing a set of
lipid species containing a common head group fragment. Lipid
species were detected with the following scans: PC, SM, and
lysoPC, [M+H]+ ions in positive ion mode with Precursor of 184.1
(Pre 184.1); PE and lysoPE, [M+H]+ ions in positive ion mode
with Neutral Loss of 141.0 (NL 141.0); PI, [M+NH4]+ in positive
ion mode with NL 277.0; PS, [M+H]+ in positive ion mode with
NL 185.0; PA, [M+NH4]+ in positive ion mode with NL 115.0;
CE, [M+NH4]+ in positive ion mode with Pre 369.3. SM was
determined from the same mass spectrum as PC (precursors of m/
z 184 in positive mode) [39–40] and by comparison with PC
internal standards using a molar response factor for SM (in
comparison with PC) determined experimentally to be 0.39. Acyl,
alk(en)yl (‘‘ether-linked’’) ePCs and ePEs were determined in
relation to the same diacyl standards as other PC and PE species,
and no response factors were applied. The collision gas pressure
was set at 2 (arbitrary units). The collision energies, with nitrogen
in the collision cell, were +28 V for PE, +40 V for PC (and SM),
+25 V for PI, PS and PA, and +30 V for CE. Declustering
potentials were +100 V for all lipids except CE, for which the
declustering potential was +225 V. Entrance potentials were
+15 V for PE, +14 V for PC (and SM), PI, PA, and PS, and
+10 V for CE. Exit potentials were +11 V for PE, +14 V for PC
(and SM), PI, PA, PS, and +10 V for CE. The mass analyzers were
adjusted to a resolution of 0.7 u full width at half height. For each
spectrum, 9 to 150 continuum scans were averaged in multiple
channel analyzer (MCA) mode. The source temperature (heated
nebulizer) was 100uC, the interface heater was on, +5.5 kV or
24.5 kV were applied to the electrospray capillary, the curtain gas
was set at 20 (arbitrary units), and the two ion source gases were
set at 45 (arbitrary units).
The background of each spectrum was subtracted, the data
were smoothed, and peak areas integrated using a custom script
and Applied Biosystems Analyst software. The data were
isotopically deconvoluted, and the lipids in each class were
quantified in comparison to the internal standards of that class,
because various molecular species within the same class ionize
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similarly [22]. The first and typically every 11th set of mass spectra
were acquired on the internal standard mixture only. Peaks
corresponding to the target lipids in these spectra were identified
and molar amounts calculated in comparison to the internal
standards on the same lipid class. To correct for chemical or
instrumental noise in the samples, the molar amount of each lipid
metabolite detected in the ‘‘internal standards only’’ spectra was
subtracted from the molar amount of each metabolite calculated in
each set of sample spectra. The data from each ‘‘internal standards
only’’ set of spectra was used to correct the data from the following
10 samples. Finally, the data were corrected for the fraction of the
sample analyzed and normalized to the sample volume to produce
data in the unit of nmol/ml.
Strategies used in Selection of Lipid Biomarkers
Two strategies were used in selecting individual apparent lipid
species biomarkers from hundreds of detected species. The first
strategy was filtration. To narrow the number of potential
candidates from 390 apparent lipid species, the species that
cannot be clinically used in diagnosis of prostate cancer were
filtered, due to too low concentration to detect, insignificant
difference between patient and control groups, or too closed levels
of plasma concentrations in two groups (although the difference
may be statistically significant) to interpret. Criteria for retention
were: 1) difference in mean plasma lipid concentration is highly
significant (p,0.01) between patient and control groups; 2)
changes in mean plasma lipid concentration is .2-fold (up or
down); and 3) mean plasma lipid concentration is .10 nmol/ml.
Apparent lipid species that fulfilled all three criteria were selected
as potential candidates of plasma lipid biomarkers. The second
strategy provided additional differentiation of cancer and control
samples, in order to demonstrate that the selected candidates are
not only clinically useful and applicable, but also they are highly
sensitive, specific and accurate in differentiation of prostate cancer
from controls. After analysis with bioinformatics methods, any
apparent lipid species of selected potential candidates will be
selected as individual plasma lipid biomarker in diagnosis of
prostate cancer, if it met these criteria: 1) sensitivity above 80%; 2)
specificity above 50%; 3) all of Precision, Recall, F-measurement
and Area under (ROC) curve above 80%.
Software and Programs Used in Statistical and
Bioinformatics Analysis
The T-Test in SPSS18 software was used to compare mean
plasma concentrations of 390 apparent lipid species between
control and patient groups. The significant p value was set at 0.01
in filtration procedures. The T-Test was also used in comparison
of mean ages between control and patient groups. The significant
p value was set at 0.05.
GenSpring11, Gim2 and Windows Paint software and pro-
grams were used to perform and graph charts of Principal
Component Analysis (PCA) and Hierarchical Clustering Analysis
(HCA).
Weka 3.73 version software was used in bioinformatics analysis:
Simple logistics classification algorithm and InfoGain, a supervised
attribute ranking method were used to rank individual apparent
lipid species and lipid class according to their predictive powers in
differentiation of patients with prostate cancer from the controls;
RandomForest classification algorithm and 10-fold cross valida-
tion were used to estimate the performance of a predictive model.
For ‘‘unknown prediction’’, models were established in a training
set, which contained populations with ‘‘known features’’, such as
white patient. All subjects within the same ‘‘known feature’’, such
as white patient, were randomly grouped (10 iterations in this
study). The predictive powers were repeatedly cross validated
among 10 iterations. The program determined average predictive
power, which indicated if a satisfactory model was established in
the training set. Then the satisfactory model with each ‘‘known
feature’’ was used to predict (to validate) predictive power in
subjects with each mirrored ‘‘unknown feature’’, such as black
patient, in the test set. Higher predictive power in the training set
indicates smaller variances among 10 randomly grouped iterations
with ‘‘known feature’’. Higher predictive powers in the test set
suggest a smaller variance between the paired ‘‘known’’ and
‘‘unknown’’ populations.
Chi-Square test in SPSS 18 software was used to compare the
distribution of controls and patients between the first half (top
portion) and the second half (bottom portion) with higher plasma
lipid concentrations in Figure S1. Chi-Square test was also used to
compare the ratios of Black to White, biopsy to prostatectomy,
high and low grade of prostate cancer between the first and second
halves. The significant p value was set at 0.05 for all results from
Chi-Square tests.
Ethics
This study was approved by the Institutional Review Board at
the University of Mississippi Medical Center as an exempt
investigation, in which obtaining consent from participants was
not required, because all of obtained specimens used in this study
were pre-collected by other organizations. The protocols for
sample collection had been approved by their Institutional Review
Boards. Patients had given their written consent before donation of
plasma samples. In this study, no identifiable information, such as




The entire study included 141 subjects including 105 patients
with prostate cancer and 36 male controls. Among the patients, 61
(58.1%) were Caucasian (‘‘white’’), 42 (40%) were African
American (‘‘black’’); and 2 were of unknown ethnic origins.
Among the 36 controls, 24 (66.7%) were Caucasian and 12
(33.3%) were African American. There was no difference in racial
ratio between patient and control groups (p = 0.55), although there
were significantly more Caucasians than African Americans in the
entire study (85 Caucasians, and 54 African Americans,
p = 0.0022). The average age at time of sample collection was
63.668.5 for patients and 57.5615.3 for controls (p = 0.0032).
Information on Gleason grade was available for 100 out of 105
patients: 2 patients had Gleason score of 5, 55 had Gleason score
of 6, 35 had Gleason score of 7, and 8 had Gleason score above 7.
Thus, 90% of patients had Gleason score of 6 or 7. Information on
other clinical conditions that might influence lipid metabolism
such as hyperlipidemia, diabetes, other malignancies and medica-
tions was not available for patients. Clinical information for 36
male controls was as following: 10 patients had their wellness
check and denied significantly clinical manifestations; 14 had
hypertension; 6 had osteoarthritis; and 1 to 2 patients had a history
of one or more of following: hyperlipidemia, back pain, obesity,
diabetes, Gout, bipolar disorder, seizure, or gastroesophageal
reflux disease. None had a history of cancer including prostate
cancer. The mean serum PSA level for controls was 0.85 ng/ml.
Lipid Profiling of 390 Apparent Lipid Species
Plasma lipid profiles including 390 individual apparent lipid
species from 13 classes of phospholipids and cholesteryl-esters (CE)
Lipid Marker for Prostate Cancer
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were determined by lipidomics for 141 plasma samples (105 from
patients and 36 from controls). The most significant difference in
mean plasma concentration between patient and control groups
was found in lysophosphatidylcholine (LPC) with the fatty acyl
chain 22:6 [LPC(22:6)] (p = 1.75610220). The highest mean
plasma concentration of a cholesteryl-ester species was CE(18:2)
(11.564.36 nmol/ml in patients, 10.9964.8 nmol/ml in controls,
p = 0.144). The highest mean plasma concentration of a polar lipid
species was PC(34:2) (0.9460.41 nmol/ml in patients,
0.5860.17 nmol/ml in controls, p = 0.00115). The significant fold
change in mean plasma concentration of these apparent lipid
species between patient and control groups ranged from positive
22.7-fold for dihydrosphingomyelin (DSM) with 16:0
[(DSM(16:0)] (p = 3.85610219) to negative 20.8-fold for PC(30:1)
(p = 9.58610204). The complete list of mean plasma concentra-
tions in patient and control groups, p values and fold changes
between patient and control groups for each of 390 species is
provided in Table S1.
Identification of Individual Apparent Lipid Species as
Biomarker
According to the criteria described in the Patients and Methods
section, 335 out of 390 species were removed by the first strategy,
filtration. Only 35 apparent lipid species were selected as potential
candidates of lipid biomarkers for diagnosis of prostate cancer
(Table 1). For these 35 selected apparent lipid species, the
difference in mean plasma concentration between patient and
control groups was highly significant (p,0.01), the change in
mean plasma concentration (increase or decrease) between patient
and control groups was $2 fold, and the mean plasma
concentration was $10 pmol/ml (15 times the detection cut-off
value in either patients, controls, or both). The second strategy
provided additional differentiation of cancer and control samples
by demonstrating whether each of 35 candidates had enough
predictive power in diagnosis of prostate cancer. Using bioinfor-
matic methods, the 35 candidates were ranked as top 1 through
top 35 according to their InfoGain values. Only 12 out of 35
potential candidates were identified as individual plasma lipid
biomarkers, because each of these 12 identified apparent lipid
species fulfilled all of criteria: sensitivity (true positive) above 80%,
specificity (1-true false positive) above 50% and all of Precision,
Recall, F-measurement and Area under (ROC) curve above 80%
in differentiation of patients with prostate cancer from controls (as
bolded and italic in Table 1).
Identification of Lipid Classes as Biomarkers
The detected 390 individual plasma apparent lipid species
belonged to 12 classes of phospholipids and one group of
cholesteryl esters. The concentration for each lipid class was
calculated by adding all of measured individual species in that
class. As shown in Table 2, all lipid classes had increased plasma
concentrations in patients as compared to controls except
phosphatidic acid (PA), which had a significantly decreased
plasma concentration in patients. LPC was the only lipid class,
within which every detected individual apparent lipid species had
a significantly elevated plasma concentration in patient group as
compared to control group (details not shown). In the rest of the
lipid classes, some apparent lipid species were up, while others
were down in their plasma concentration in patients vs. controls.
The differences in plasma lipid concentrations between patients
and controls were statistically significant in the majority of lipid
classes except lysophosphatidylethanolamine (LPE) and phospha-
tidylserine (PS). However, when the same criteria used in selection
of biomarkers from individual apparent lipid species were applied
to the lipid classes, only the lipid classes PE, ePE and ePC could be
considered to be biomarkers in diagnosis of prostate cancer. Using
lipid classes as biomarkers for diagnosis of prostate cancer is not an
ideal choice, because potentially useful information is lost by
arbitrarily combining measured values (based on lipid class
assignment) for individual apparent lipid species.
Effect of Grouping Multiple Biomarkers on Diagnosis of
Prostate Cancer
To demonstrate if using more lipid biomarkers together within
35 candidates is able to increase the predictive power for diagnosis
of prostate cancer, seven groups of apparent lipid species with
different numbers of candidates were manually grouped: top 5 (top
1 through 5, 5 candidates together), 10 (top 1 through 10, 10
candidates together, etc.), 15, 20, 25, 30 and 35 (all of 35
candidates together). The results show that in any manually
assembled group with more lipid markers together had higher
sensitivity, specificity and accuracy in diagnosis of prostate cancer
as compared to any of individual lipid biomarkers. Among these
manually assembled groups, the group of 15 (top 1 through top15,
15 biomarkers together) was the best combination with the
strongest predictive powers in diagnosis of prostate cancer: it had
the highest sensitivity (93.6%), the highest specificity (90.1%),
higher accuracy (97.3%) as shown in Figure 1, and the highest
Precision, Recall and F-Measure (93.7%, 93.6% and 93.6%,
respectively, data not shown in Figure 1).
To potentially reduce the number of biomarkers to facilitate
practical incorporation into the workflow of clinical laboratories
and to make the results most amenable to interpretation by
clinicians, bioinformatics analyses were performed on the various
combinations from two lipid biomarkers together (top 2) through
15 lipid biomarkers together (top 15) as shown in Table 3. As an
example, if top three lipid biomarkers, LPC(18:1), LPC(20:4) and
PC(40:7) (Top 3) were used together, the combination would
provide a sensitivity of 91.5%, specificity of 84.3% and accuracy
(ROC Area) of 95.9% in differentiating patients with prostate
cancer from male controls. Grouping lipid classes, as opposed to
individual species, also increased sensitivity, specificity, and
accuracy in diagnosis of prostate cancer as compared to any
single lipid class. For example, the top 2 classes of lipids (class LPC
and PE) together had a sensitivity of 88.7%, a specificity of 81.5%
and an accuracy of 94.4% (data not shown). However, the
predictive powers from grouping more lipid classes were lower
than from grouping multiple individual plasma apparent lipid
species.
Characteristics of Identified Plasma Lipid Biomarkers
Because using top 15 lipid biomarkers together had the best
predictive power in diagnosis of prostate cancer, the characteristics
in this group of apparent lipid species were further analyzed.
Principal components analysis (PCA) was performed to examine
the ability to separate patient and control subjects with lipid
profiles of all 390 and the selected 15 apparent lipid species.
Performing PCA with lipid profiles of 390 apparent lipid species,
patient and control subjects were visually separated along the first
component in PCA, which accounted for 28.3% of the overall
variance (Figure 2, A). However, when PCA was performed with
lipid profiles of the selected 15 apparent lipid species, the first
component, along which patient and control samples were
separated, accounted for 86.9% of the overall variance in the
data (Figure 2, B). This indicates that much more variations in
these top 15 apparent lipid species are associated with the
classification of patient or control. In addition, positions of control
subjects were spatially closer than those of patient subjects when
Lipid Marker for Prostate Cancer
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either set of data was plotted, suggesting that variances in mean
plasma lipid concentration (here transformed to uncorrelated
values of space distances) in the control group were much smaller
than those in the patient group.
Hierarchical cluster analysis (HCA) is a statistical method for
finding relatively homogeneous clusters of cases based on
measured characteristics. We applied HCA combining dendro-
grams and a heatmap to cluster both entity (15 apparent lipid
species) and condition (141 subjects) with panels of characteristics
at the left side in Figure S1. The HCA analysis showed that 15
apparent lipid species were patterned into 4 clusters: DSM(16:0),
ether-linked phosphatidylcholines (ePCs), sphingomyelins (SMs)
and LPCs. The 15 top ranking apparent lipid species had a
tendency of gradually increasing mean plasma lipid concentration
from top (lower concentration, in blue) to bottom (higher
concentration, in red). To further analyze the data, the subjects
in the heatmap were divided into two halves: the first half
containing 70 subjects with lower plasma lipid concentration, and
the second half containing 71 subjects with higher plasma lipid
concentration. The analyzed results, as shown in Table 4,
indicated that there is a dramatically high Odds Ratio in the
presence of control and patient subjects between the first and
second half (p,0.0001, OR = 70.0). Interestingly, patient subjects
diagnosed by biopsies were significantly enriched in the second
Table 1. Top 35 individual plasma apparent lipid species as candidate biomarkers for prostate cancer (Concentration: pmol/ml).
Lipid Patients (105) Control (36) P/C p Predictive Values (%)
Species* Rank Mean SD Mean SD Fold value Sens. Spec. Prec. Recall F-meas. AUC
LPC(18:1) 1 43.4 22.8 15.8 6.2 2.7 2.63E-09 80.4 60.6 79.5 80.4 79.9 87.4
LPC(20:4) 2 14.6 9.4 4.6 2.0 3.2 1.71E-15 88.7 79.7 88.5 88.7 88.5 93.3
PC(40:7) 3 16.9 10.0 7.6 3.0 2.2 4.37E-11 86.5 68.0 86.3 86.5 85.6 89.8
LPC(18:0) 4 74.6 39.7 30.3 10.7 2.5 3.00E-08 80.9 56.9 79.6 80.9 79.3 87.9
LPC(16:0) 5 240.3 121.4 85.0 38.8 2.8 2.03E-06 70.3 40.8 68.1 70.3 69.0 64.1
ePC(38:4) 6 27.7 14.0 13.0 5.0 2.1 3.01E-08 82.3 66.5 81.6 82.3 81.8 87.8
PC(38:4) 7 380.9 200.1 181.5 72.4 2.1 3.65E-05 80.9 55.1 79.7 80.9 79.0 85.4
PC(38:5) 8 136.0 68.1 61.0 23.3 2.2 8.50E-06 81.6 60.8 80.5 81.6 80.5 84.3
SM(18:1) 9 67.9 45.2 22.8 14.5 3.0 1.05E-09 81.2 44.2 81.3 81.2 77.3 77.8
SM(16:1) 10 76.6 45.0 30.3 16.8 2.5 6.71E-09 81.2 50.4 79.8 81.2 78.8 81.0
DSM(16:0) 11 12.2 12.0 0.5 0.8 22.7 3.85E-19 74.5 25.5 55.5 74.5 63.6 50.0
SM(16:0) 12 494.9 276.2 200.9 97.3 2.5 1.20E-06 80.1 51.2 79.0 80.1 77.6 83.4
ePC(36:1) 13 13.3 8.9 5.5 2.0 2.4 6.30E-10 76.6 48.2 74.2 76.6 74.3 83.5
SM(18:0) 14 102.6 62.1 36.8 26.1 2.8 1.72E-06 80.9 56.9 79.6 80.9 79.3 80.3
ePC(36:2) 15 25.4 12.3 12.6 4.9 2.0 1.72E-07 87.1 78.6 87.1 87.1 87.1 91.8
C19:2 CE 16 28.0 32.3 3.1 7.8 9.0 9.94E-14 73.0 54.3 72.6 73.0 72.8 74.4
ePC(38:1) 17 10.3 6.7 4.2 1.8 2.5 4.14E-11 73.8 30.8 67.1 73.8 66.5 81.9
LPC(18:2) 18 61.7 35.2 28.0 13.5 2.2 1.26E-06 80.4 52.3 78.7 80.4 78.6 87.9
PC(34:1) 19 343.5 193.7 164.0 71.4 2.1 1.84E-04 73.8 39.9 69.7 73.8 70.1 82.5
SM(24:0) 20 89.3 53.8 31.8 25.1 2.8 3.78E-06 78.0 52.3 76.1 78.0 76.2 82.7
PE(36:2) 21 18.4 14.0 7.8 5.2 2.4 3.93E-09 78.7 47.1 77.1 78.7 75.6 82.8
C19:3 CE 22 37.9 62.2 3.7 7.4 10.3 8.31E-11 74.5 25.5 55.5 74.5 63.6 50.0
C20:1 CE 23 22.1 25.8 7.6 12.1 2.9 3.02E-07 74.5 25.5 55.5 74.5 63.6 50.0
C20:0 CE 24 56.8 104.6 14.5 47.4 3.9 6.50E-07 74.5 25.5 55.5 74.5 63.6 50.0
PC(36:1) 25 64.4 43.3 31.4 23.6 2.1 8.42E-05 75.2 33.1 71.3 75.2 68.3 67.3
C18:0 CE 26 42.5 38.8 17.5 26.5 2.4 6.45E-04 67.4 23.1 54.0 67.4 60.0 41.9
PC(30:1) 27 0.7 5.0 14.3 18.7 220.9 9.58E-04 80.1 45.7 80.7 80.1 76.2 61.9
SM(22:0) 28 16.9 44.0 63.0 78.6 23.7 5.51E-04 77.3 46.6 74.9 77.3 74.4 63.0
C21:3 CE 29 28.6 39.6 9.7 16.6 3.0 3.53E-06 74.5 25.5 55.5 74.5 63.6 50.0
C19:1 CE 30 207.9 232.1 72.4 120.3 2.9 1.60E-05 74.5 25.5 55.5 74.5 63.6 51.0
C17:0 CE 31 23.9 29.3 7.2 10.4 3.3 4.19E-05 74.5 25.5 55.5 74.5 63.6 50.0
C17:1 CE 32 16.9 17.3 6.5 10.6 2.6 1.17E-04 74.5 25.5 55.5 74.5 63.6 50.0
C14:0 CE 33 43.5 45.4 20.6 31.8 2.1 5.16E-03 74.5 25.5 55.5 74.5 63.6 50.0
C19:0 CE 34 73.3 99.2 24.9 38.9 2.9 1.80E-04 74.5 25.5 55.5 74.5 63.6 50.0
C22:5 CE 35 30.4 40.4 14.0 17.1 2.2 2.15E-03 74.5 25.5 55.5 74.5 63.6 50.0
*Apparent lipid species identities are based on the mass/charge ratio of the intact lipid ion and one characteristic fragment. Sens. = Sensitivity, Spec. = Specificity,
Prec. = Precision, F-Meas. = F-measure.
doi:10.1371/journal.pone.0048889.t001
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half as compared with those diagnosed by prostatectomies. When
the subjects were stratified by age, race and Gleason grade of
patients with prostate cancer, it showed that the second half
(higher concentrations of individual apparent lipid species) had
more black patients, especially black patients with old age, as
compared with the first half. Cancer grade and overall age were
not significantly different between two halves.
Table 2. Lipid classes in differentiation of prostate cancer (Concentration: nmol/ml).
Lipid Patients (105) Controls (36) P/C p Predictive values (%)
Class Rank Mean SEM Mean SEM fold value Sens. Spec. Prec. Recall F-meas. AUC
LPC 1 0.45 0.02 0.17 0.01 2.7 1.08E-11 74.5 25.5 55.5 74.5 63.6 49.3
PE 2 0.11 0.01 0.04 0.00 2.5 1.09E-08 83.7 59.7 83.3 83.7 82.1 85.3
ePE 3 0.02 0.00 0.01 0.00 2.5 1.93E-07 80.9 53.3 79.9 80.9 78.6 82.7
SM 4 1.24 0.07 0.57 0.03 2.2 5.73E-08 79.4 58.3 78.1 79.4 78.4 86.4
ePC 5 0.32 0.01 0.16 0.01 2.0 6.87E-10 81.6 59.0 80.5 81.6 80.2 89.1
LPE 6 0.01 0.00 0.01 0.00 1.2 4.87E-01 74.5 25.5 55.5 74.5 63.6 49.3
PC 7 3.69 0.15 1.94 0.10 1.9 4.23E-10 80.1 58.5 78.9 80.1 79.0 88.9
PA 8 0.00 0.00 0.00 0.00 21.5 1.01E-02 75.2 29.4 73.1 75.2 66.4 53.9
PE-Cer 9 0.00 0.00 0.00 0.00 3.3 2.21E-06 75.9 46.1 73.1 75.9 73.3 83.0
CE 10 18.36 0.63 13.67 1.15 1.3 3.16E-04 76.6 35.4 75.5 76.6 70.1 61.7
PI 11 0.15 0.01 0.09 0.01 1.6 2.88E-05 76.6 40.9 73.9 76.6 72.3 72.2
ePS 12 0.00 0.00 0.00 0.00 2.3 3.40E-02 74.5 25.5 55.5 74.5 63.6 50.0
PS 13 0.00 0.00 0.00 0.00 1.2 6.34E-01 74.5 25.5 55.5 74.5 63.6 50.0
Sens. = Sensitivity, Spec. = Specificity, Prec. = Precision, F-Meas. = F-measure.
doi:10.1371/journal.pone.0048889.t002
Figure 1. Effect of multiple individual lipid species in diagnosis of prostate cancer. The points indicated by the two head arrows are the
predictive powers of top 15 plasma apparent lipid species when they are used together in diagnosis of prostate cancer. Using top 15 plasma
apparent lipid species has the highest sensitivity (93.6%), the highest specificity (90.1%), and higher accuracy (ROC Area, 97.3%) in the diagnosis of
prostate cancer as compared with using any other combination of different numbers.
doi:10.1371/journal.pone.0048889.g001
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It is unclear whether imbalanced compositions of race and age
in this study cohort influenced the predictive power of the selected
15 apparent lipid species in diagnosis of prostate cancer. To clarify
this issue, an ‘‘unknown prediction’’ method was applied. The
results of unknown prediction are shown in Table 5. Using
RandomForrest and 10-fold cross validation programs, satisfactory
models in the training set were demonstrated by their high
predictive powers in each group of subjects with a ‘‘known
feature’’, such as ‘‘white patient or control’’, ‘‘young patient or
control’’, and in ‘‘random group 1’’ subjects. These results
suggested that variability within any out of 10 iterations of
subjects with a ‘‘known feature’’ did not affect the predictive
powers of other iterations. Each group of subjects with a
corresponding ‘‘unknown feature’’, such as ‘‘black patient or
control’’, ‘‘old patient or control’’, and in ‘‘random group 2’’
subjects in the test set, was cross validated by its corresponding
established model in the training set. Similarities in high predictive
powers in each set of paired groups indicated that the variability
between the paired features (known and unknown), such as white
vs. black, young vs. old and random group 1 subjects vs. random
group 2 subjects, did not affect the selected 15 selected lipid
biomarkers in differentiation of patients with prostate cancer from
controls. Thus, imbalance of age and race between patient and
control groups did not affect the ability of the selected 15 lipid
biomarkers to differentiate patients from controls in this study
cohort.
Among the 355 un-selected apparent lipid species, 43 (12.11%)
of the lipid molecules contained saturated fatty acid chains only
(no unsaturated fatty acid chains). While within the 35 selected
apparent lipid species, 12 (34.3%) lipid molecules contain
saturated fatty acid chains only. The difference in percentage of
apparent lipid species containing saturated fatty acid only was
highly significant between the selected 35 candidates and those un-
selected apparent lipid species (p,0.001, diagnostic odds ratio was
Table 3. Comparison of predictive powers among groups with different numbers of identified plasma lipid biomarkers.
Numbers of Predictive values (%)
Biomarkers Sensitivity Specificity Precision Recall F-measure ROC Area
Top2 87.9 83.1 88.3 87.9 88.1 94.0
Top3 91.5 84.3 91.4 91.5 91.4 95.9
Top4 90.1 82.0 89.9 90.1 90.0 95.0
Top5 90.8 85.9 90.9 90.8 90.8 96.3
Top6 89.4 83.6 89.5 89.4 89.4 95.7
Top7 90.1 82.0 89.9 90.1 90.0 95.6
Top8 90.1 83.8 90.1 90.1 90.1 96.1
Top9 91.5 86.1 91.5 91.5 91.5 96.5
Top10 91.5 86.1 91.5 91.5 91.5 96.5
Top11 92.2 88.2 92.3 92.2 92.2 97.3
Top12 92.9 90.3 93.1 92.9 93.0 97.5
Top13 92.2 88.2 92.3 92.2 92.2 97.2
Top14 92.2 88.2 92.3 92.2 92.2 97.3
Top15 93.6 90.5 93.7 93.6 93.6 97.3
doi:10.1371/journal.pone.0048889.t003
Figure 2. Comparison of Principal Component Analysis (PCA) with 390 and 15 selected plasma apparent lipid species. A: The first
component in PCA cross all 390 detected plasma apparent lipid species accounts for 28.3% of the overall variance; B: The first component in PCA
cross 15 selected plasma apparent lipid biomarkers accounts for 86.9% of the overall variance.
doi:10.1371/journal.pone.0048889.g002
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3.79 with a 95% confidence interval of 1.64–8.67). These results
suggested that the apparent lipid species with only saturated fatty
acids chain only might play certain roles in pathogenesis of
prostate cancer.
The mass spectra of top 15 apparent lipid species in
representative patient and control samples are shown in Figure 3.
Identified lipid species were exclusively phosphocholine-containing
phospholipids, including 3 ePCs, 3 PCs, 4 LPCs and 5 SM/DSMs.
Discussion
In clinical practice, PSA is the most commonly used biomarker
for prostate cancer. However there is a substantial overlap in
serum PSA level between patients with and without prostate
cancer. No single PSA cutoff value can satisfactorily provide a
simultaneously higher sensitivity and specificity in diagnosis of
prostate cancer. Taking an example, one study showed that a PSA
cutoff value of 1.1 ng/ml had a sensitivity of 83.4% with a
specificity of 38.9%; that of 4.1 ng/ml had a sensitivity of 20.5%
with a specificity of 93.8%; and the area under (ROC) curve was
68.2% [41–42]. Other newly reported biomarkers have been less
systemically studied for their sensitivity, specificity and accuracy in
diagnosis of prostate cancer. As compared to PSA, plasma lipid
biomarkers identified in this study had much higher sensitivity,
specificity and accuracy simultaneously in diagnosis of prostate
cancer. It is especially true when multiple lipid markers were used
together. For example, using the top 3 plasma lipid biomarkers
together achieved a much higher predictive values in differenti-
ation of prostate cancers from controls as compared to PSA. Of
course, further investigations are needed to demonstrate if there
are overestimations of sensitivity, specificity and accuracy due to
the feature selections used in this pilot study.
Human plasma contains thousands of distinct lipid species.
Although normal ranges of some lipid species have been
determined in plasma [43–44], the majority have not. Recently,
standard reference values for 500 plasma lipid molecules were
produced by lipidomics on plasma samples pooled and blended
from 100 healthy American people [23]. Many apparent lipid
species in our study overlapped with those. Although some
discrepancies were noted, comparison of mean plasma concen-
tration of the apparent lipid species detected in both studies
indicated that many values were extremely close, including several
that we identified as individual lipid biomarkers for prostate cancer
Table 4. Comparison of subject distributions and patient characteristics between upper and lower halves in the cluster of top 15
apparent lipid species.
The first half The second half p value OR 95% C.I.
Total Controls (36) 35 1
Total Patients (105) 35 70 ,0.0001 70 9.6–1430.5
Patient Characteristics
Ratio of Black to White 0.40 0.84 0.09 0.48 0.18–1.20
Ratio of biopsy to prostatectomy 0.93 4.15 0.0007 4.75 1.69–13.59
Ratio of high to low grade Pca 0.67 0.50 0.65 0.75 0.28–1.99
Patient age year-old (mean±SD) 62.8611.3 6367.92 0.92
Ratio of Black:White in young patients 0.75 0.78 0.31 2.16 0.47–10.02
Ratio of Black:White in old patients 0.27 0.93 0.07 0.92 0.06–1.30
doi:10.1371/journal.pone.0048889.t004
Table 5. Comparison of predictive values (%) of the top 15 plasma lipid biomarkers in diagnosis of prostate cancer in training set
and testing set.
Predict Group Predictive values (%) in training set Predictive values (%) in testing set
Category Sens. Spec. Prec. Recall F-m. AUC Sens. Spec. Prec. Recall F-m. AUC
White Patient 95.1 95.8 98.3 95.1 96.7 97.3 95.2 91.7 97.6 95.2 96.4 97.0
predict Control 95.8 95.1 88.5 95.8 92.0 97.3 91.7 95.2 84.6 91.7 88.0 97.0
black Weighted
average
95.3 95.6 95.5 95.3 95.3 97.3 94.4 92.5 94.7 94.4 94.5 97.0
Young Patient 96.5 86.4 94.8 96.5 95.7 97.6 93.8 78.6 93.8 93.8 93.8 96.9
predict Control 86.4 96.5 90.5 86.4 88.4 97.6 78.6 93.7 78.6 78.6 78.6 96.9
old Weighted
average
93.7 89.2 93.6 93.7 93.6 97.6 90.3 82.0 90.3 90.3 90.3 96.9
Group1 Patient 92.9 86.4 95.6 92.9 94.2 95.6 94.3 85.7 94.3 94.3 94.3 94.1
predict Control 86.4 92.9 79.2 86.4 82.6 95.6 85.7 94.3 85.7 85.7 85.7 94.1
group 2 Weighted
average
91.3 87.9 91.7 91.3 91.4 95.6 91.8 88.2 91.8 91.8 91.8 94.1
Sens. = Sensitivity, Spec. = Specificity, Prec. = Precision, F-m. = F-measure, AUC=Area under (ROC) curve.
doi:10.1371/journal.pone.0048889.t005
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in our study. For example, LPC(18:1), which was ranked as top 1
plasma lipid biomarker in our study, mean plasma concentration
was 14.8 nmol/ml in the referenced study and 15.82 pmol/ml (i.e.
nmol/ml) in the control group of our study. Similarly in
LPC(20:4), the second top plasma lipid biomarker in our study,
mean plasma concentration was 5.37 nmol/ml in the referenced
study, and 4.61 pmol/ml in the control group of our study. The
reason for some discrepancies between two studies is unclear. In
addition to the great variability in individual subject and lipid
species, other possible reasons for these discrepancies could be the
bias between different detecting centers, or biochemical interac-
tions occurred in repeated freezing-thawing process in the
referenced study, or the smaller sample size of the control group
in our study. It is desirable to establish an international standard
reference values with normal ranges for all plasma lipid species to
meet with the increasing demand in lipid research and clinical
practice.
Univariate analysis of one apparent lipid species is unlikely to be
sufficient to discriminate prostate cancer patients from controls
because of considerable variation of plasma lipid concentrations. A
combination of multiple plasma lipid biomarkers with multivariate
analysis and various classification algorithms was demonstrated
herein to have enhanced predictive power in the diagnosis of
prostate cancer in our study. A similar effect was reported by
Landers et al [45], who found that combined 4 gene markers
greatly increased sensitivity in discriminating prostate cancer from
benign prostatic hyperplasia (BPH), and by Petricoin et al [46],
who applied a genetic algorithm and clustering analysis to abstract
discriminatory patterns of proteomics data from thousands of
protein and peptide molecules to separate ovarian cancers from
controls with a sensitivity of 100%, specificity of 95%, and positive
predictive value of 94%. Measurement of a panel of a few plasma
lipid molecules, for example 3 to 15 apparent lipid species may be
feasible in routine clinical laboratories. The test requires very small
amount of blood (3 ml of plasma), which can be obtained with
minimally invasive procedures. The test results could be obtained
within an hour. Together with all of these advantages of lipidomic
technology, a new diagnostic model based on statistical and
bioinformatic analysis with high predictive values could be used in
diagnosis of prostate cancer in the near future. This study, once
validated prospectively in our ongoing study, or confirmed by
other researchers, potentially will have a revolutionary impact on
diagnosis and study of the pathogenesis of prostate cancer, and
other diseases.
Overall, patients with prostate cancer had increased plasma
lipid concentrations in all lipid classes except PA, which was
significantly lower in patients with prostate cancer. This imbalance
in plasma concentrations among lipid classes could be caused by
increased synthesis of other phospholipids in prostate cancer
resulting in over-consumption of PA, because PA is the precursor
for synthesis of many other phospholipids [47]. It is unclear why
the plasma concentrations of individual lipid species in same lipid
class were greatly varied: some increased and others decreased in
the patients. One possible mechanism for this imbalance is that
prostate cancer cells regulate the enzymes that control lipid
metabolic pathways of not only synthesizing but also remodeling
phospholipids. The expression level of one of these enzymes,
lysophosphatidylcholine acyltransferase 1 (LPCAT1), a key
enzyme in Lands’ cycle remodeling pathway, correlated with the
progression of prostate cancer [48]. We also found that nuclear
translocation of soluble phospholipase A2 (sPLA2) was up-
regulated in prostate cancer tissues as compared with benign
prostatic tissues (unpublished), but it is not clear whether the
nuclear translocation of sPLA2 is associated with remodeling of
phospholipid. The fact that all identified top 15 apparent lipid
species were species containing phosphocholine is very intriguing.
This result might suggest up-regulation of phosphocholine
metabolism in patient with prostate cancer, and is consistent with
Figure 3. Mass spectra of phosphocholine-containing lipids (Pre-184 positive mode, including biomarker species. A: Spectra of 15
selected apparent lipid species in a representative patient with prostate cancer. B: Spectra of 15 selected apparent lipid species in a representative
male control. Spectral intensities were normalized to that of internal standard LPC(13:0). The intensities of phosphocholine-containing internal
standards (I.S.) are indicated in green. The intensities of the identified biomarkers are shown in red. Internal standards and biomarkers (15 selected
apparent lipid species) are labeled.
doi:10.1371/journal.pone.0048889.g003
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previous findings that high grade prostate cancer tissues had
higher concentration of phosphocholine as compared with low
grade prostate cancer [49].
This preliminary study has several limitations. First, more than
90% of plasma samples were obtained from prostate cancer
patients with a Gleason score of 6 or 7, which made it impossible
to correlate the identified plasma lipid biomarkers with the severity
of the prostate cancer, as well as to the patients with metastasis or
benign changes. Second, due to incomplete information on the
patients’ serum PSA level at the time of samples’ collection, and to
the lack of information on patients’ outcomes, we were unable to
compare the predictive power of the identified lipid biomarkers
with that of PSA in the same study cohort. Therefore, at this point,
the identified plasma apparent lipid species might serve as
diagnostic biomarkers only, but not as prognostic and screening
biomarkers. As well, the specificity of these identified lipid
biomarkers has not been tested for other cancers and metabolic
disorders. Even if there are limitations in the study, it is a
pioneering work, exploring a new approach to seeking biomarkers
for prostate cancer and other diseases.
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